Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David G Warnock

Showing results (51-60 of 209) with videos related to

Pageof 21
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 9, 2014
Similar names for similar biologicsNicole Casadevall, Thomas Felix, Bruce E Strober, et al.
Contributions to Nephrology|January 15, 2004
Vascular grafts for hemodialysis: types, sites and techniquesDavid G Warnock, Ashita J Tolwani, Michael Gallichio, et al.
Human Molecular Genetics|May 5, 2023
Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry diseaseValeria Nikolaenko, David G Warnock, Kevin Mills, et al.
Nephron|June 30, 2025
Recent Advances in Understanding the Pathophysiology of Fabry DiseaseDavid G Warnock, Aleš Linhart, Anthony J Bleyer, et al.
Kidney International Reports|April 11, 2020
Current and Investigational Therapeutics for Fabry DiseaseAndrew Felis, Michael Whitlow, Abigayle Kraus, et al.
Pediatric Nephrology (Berlin, Germany)|May 1, 2016
Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase betaShuichi Ito, Masao Ogura, Koichi Kamei, et al.
Journal of Medical Genetics|January 26, 2021
Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry diseaseAlbina Nowak, Felix Beuschlein, Visnuka Sivasubramaniam, et al.
American Journal of Nephrology|April 5, 2012
Acute kidney injury and mortality in hospitalized patientsHenry E Wang, Paul Muntner, Glenn M Chertow, et al.
Drug Safety|April 28, 2015
Oral anticoagulants and risk of nephropathyVinay Narasimha Krishna, David G Warnock, Nakshatra Saxena, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 29, 2013
Comparison of absolute serum creatinine changes versus Kidney Disease: Improving Global Outcomes consensus definitions for characterizing stages of acute kidney injuryHenry E Wang, Gaurav Jain, Richard J Glassock, et al.
Pageof 21

Showing results (51-60 of 209) with videos related to

Sort By:
Pageof 21
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 9, 2014
Similar names for similar biologicsNicole Casadevall, Thomas Felix, Bruce E Strober, et al.
Contributions to Nephrology|January 15, 2004
Vascular grafts for hemodialysis: types, sites and techniquesDavid G Warnock, Ashita J Tolwani, Michael Gallichio, et al.
Human Molecular Genetics|May 5, 2023
Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry diseaseValeria Nikolaenko, David G Warnock, Kevin Mills, et al.
Nephron|June 30, 2025
Recent Advances in Understanding the Pathophysiology of Fabry DiseaseDavid G Warnock, Aleš Linhart, Anthony J Bleyer, et al.
Kidney International Reports|April 11, 2020
Current and Investigational Therapeutics for Fabry DiseaseAndrew Felis, Michael Whitlow, Abigayle Kraus, et al.
Pediatric Nephrology (Berlin, Germany)|May 1, 2016
Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase betaShuichi Ito, Masao Ogura, Koichi Kamei, et al.
Journal of Medical Genetics|January 26, 2021
Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry diseaseAlbina Nowak, Felix Beuschlein, Visnuka Sivasubramaniam, et al.
American Journal of Nephrology|April 5, 2012
Acute kidney injury and mortality in hospitalized patientsHenry E Wang, Paul Muntner, Glenn M Chertow, et al.
Drug Safety|April 28, 2015
Oral anticoagulants and risk of nephropathyVinay Narasimha Krishna, David G Warnock, Nakshatra Saxena, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 29, 2013
Comparison of absolute serum creatinine changes versus Kidney Disease: Improving Global Outcomes consensus definitions for characterizing stages of acute kidney injuryHenry E Wang, Gaurav Jain, Richard J Glassock, et al.
Pageof 21